Pliant Therapeutics announced that the latest data from the Phase 1 clinical trial of its investigational drug Pln-101095 for patients with immune checkpoint inhibitor (ICI)-refractory solid tumors will be presented in a special report at the 2026 American Association for Cancer Research (AACR) Annual Meeting.

Pliant Therapeutics announced that the latest data from the Phase 1 clinical trial of its investigational drug Pln-101095 for patients with immune checkpoint inhibitor (ICI)-refractory solid tumors will be presented in a special report at the 2026 American Association for Cancer Research (AACR) Annual Meeting.

老虎证券2026/04/18 17:43

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

This groundbreaking study aims to evaluate the safety and preliminary efficacy of Pln-101095 in patients with advanced solid tumors, providing new potential directions for tumor immunotherapy.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

You may also like

Crypto prices